Abstract: A computer-implemented method for generating one or more modified amino acid sequences comprises obtaining, via one or more processors, one or more candidate amino acid sequences and characteristic data associated with the one or more candidate amino acid sequences; classifying, via the one or more processors, the one or more candidate amino acid sequences into a first set of high-viscous amino acid sequences and a second set of low-viscous amino acid sequences using a predictive model, the classifying comprising: calculating one or more viscosity predictions based on the one or more candidate amino acid sequences and the obtained characteristic data; and determining the first set of high-viscous amino acid sequences and the second set of low-viscous amino acid sequences based on the one or more viscosity predictions and a predetermined viscosity threshold, wherein the first set of high-viscous amino acid sequences comprises at least one candidate amino acid sequence; and generating, via the one or more proce

Abstract: The clinical potential of multispecific antibodies like bispecific and trispecific antibodies shows great promise for targeting complex diseases. However, the generation of those molecules presents great challenges particularly in regard to achieving acceptable expression levels free from mis-paired polypeptides. The presently claimed invention is directed to multispecific antigen binding proteins which improve upon existing charge pair technologies by redistributing the engineered charges within the CH3 regions of a heteromultimer.

Abstract: The present invention relates to heterodimers comprising antibody CH3 domains and mutations useful for the facilitation of the formation of heterodimers. Methods of optimizing purification of the heterodimers at certain pHs in also disclosed.

Abstract: The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies directed to IL-13. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided. Additionally, methods of using these antibodies to treat patients are also provided.

Abstract: Presented herein are methods directed to engineering monoclonal antibodies and antibody variants to improve stability and their production in culture. Specifically, the monoclonal antibodies can be engineered at heavy chain residue 56 (AHo numbering) to a glycine, alanine, or serine, and/or engineered at position 80 (AHo) to be a hydrophobic residue such as alanine, isoleucine, phenylalanine, leucine, methionine, or valine.